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Computational studiesa b s t r a c t
New tetracyclic benzofurocoumarin (benzopsoralen) analogues were synthesized and their inhibitory
effect on the growth of tumor cell lines was evaluated. The human tumor cell lines used were MDA
MB231 (breast adenocarcinoma), HeLa (cervix adenocarcinoma) and TCC-SUP (bladder transitional cell
carcinoma). The in vitro antitumor activity of the new benzopsoralens was discussed in terms of struc-
ture–activity relationship. Molecular docking studies with human-CYP2A6 enzymes were also carried
out with the synthesized compounds in order to evaluate the potential of these compounds to interact
with the heme group of the enzymes. The results have demonstrated that the linear compounds have
the most pronounced activity against tumor cell lines and this might be related to the better accessibility
that these compounds have to the active site in relation to the angular ones that have shown in the
majority of the cases multiple binding poses in the active site of CYP2A6.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Psoralens are natural products (linear furocoumarins) present
in several plant families, which have been shown to possess a wide
spectrum of biological activities including cytotoxic, phytotoxic,
photosensitizing, insecticidal, and antibacterial to antifungal ef-
fects.1–4 Furthermore, psoralens have been suggested as potential
therapeutics for the treatment of skin disorders (e.g. vitiligo, leuko-
derma and psoriasis),5–9 cutaneous T-cell lymphoma,10–12 autoim-
mune diseases13,14 and several types of cancer.15–24
An outstanding feature of psoralens is their ability to intercalate
into dsDNA and create covalent cross-links primarily with thymi-
dine residues.1,25 Crosslinking proceeds readily under photoactiva-
tion and potentially blocks DNA replication and transcription.
Furthermore, psoralens are known to interrupt drug metabolism,
especially by the inactivation of cytochromes P450 (CYPs);13,26
thus the P450 superfamily is suggested as one of the main drug tar-
gets. Human CYPs are a family of heme containing enzymes in-
volved in the biotransformation of xenobiotics, as well as
endogeneous molecules, and in the bioactivation of carcino-
gens.9,27,28 CYP1A and CYP2B subfamilies are particularly impor-tant due to their capacity to ‘activate’ a broad variety of
environmental contaminants leading to highly reactive metabo-
lites that react with macromolecules such as proteins, lipids and
nucleic acids.29 The inhibition of CYP1A1 and CYP1A2 has been
implicated in the antigenotoxic mechanism of several furocouma-
rins, such as bergamottin and naringin.9,30,31 Psoralen and xantho-
toxin (8-methoxypsoralen) can be oxidized at the furan ring to
form a furanoepoxide that binds to CYP2B1.32 In addition, xantho-
toxin up-regulates CYP1A1 expression.33 Psoralen can behave as a
general competitor substrate or act as a suicide inhibitor reacting
with the heme group of the P450 proteins, consequently inactivat-
ing them.26,34 Xanthotoxin, bergapten (5-methoxypsoralen) and
psoralen were found to act as suicide inactivators of human-
CYS2A6 protein in liver microsomes.35 Also, bergapten was re-
ported as a suicide inhibitor of human CYP3A4, and xanthotoxin
was found to competitively inhibit a variety of drug metabolites
catalysed by CYP3A4.36
Several research groups are engaged in the synthesis and eval-
uation of biological properties of psoralen derivatives,37,38 includ-
ing benzopsoralens.39,40 Previously in our group some psoralen
type compounds were prepared and found to inhibit the in vitro
growth of different human tumor cell lines.41,16 The angular com-
pounds derived from dibenzofuran showed the most promising
results.41b,16 In the current study, one linear analogue was pre-
pared (compound 1, Fig. 1) and tested. Other compounds, derived
from 2-hydroxycarbazole, were also synthesized, one of them
5048 C. S. Francisco et al. / Bioorg. Med. Chem. 21 (2013) 5047–5053linear (compound 2, Fig. 1), three others angular (compounds 4–6,
Fig. 1) and their biological activity was determined. Furthermore,
their binding poses in the active site of human-CYS2A6 enzymes
were evaluated by molecular docking studies (see Fig. 2), in order
to investigate their potential to interact with the heme group of the
enzymes.
2. Results and discussion
2.1. Chemistry
Compound 1 was prepared, in 27% yield, from 2-hydrox-
ydibenzofuran and ethyl 3-oxobutanoate by a Pechmann reaction
(Scheme 1).
The NMR data are consistent with the proposed structure,
namely the proton singlets of the coumarin ring at d (H) 6.47 (H-Figure 2. Molecular docking results of compounds 1, 2 and 4–6. The substrates are repr














Figure 1. Structures of the3) and 2.53 (CH3) and the signal at d (C) 159.91 for the C@O
group. The same compound was prepared before, by another
approach.42 The melting point given in the literature is lower
(200 C) than that for our compound (247–249 C). The author de-
scribes the sample as an orange red powder and the coloured
impurities may be the reason why its melting point is much lower
than in our case.
Compound 2 was synthesized by the same method starting
from 2-hydroxycarbazole, with a 33% yield. In the 1H NMR spec-
trum showed the characteristic signals for compound 2, including
the expected singlets at d (H) 8.57 (H-5) and 7.38 (H-11).
The remaining compounds were obtained from 2-hydroxy-9H-
carbazole-1-carbaldehyde 3 (Scheme 2 and 4–6) which was pre-
pared in low yield (5%) by Reimer–Tiemann formylation of
2-hydroxycarbazole. The formation of this product was conﬁrmed


























































































Scheme 2. Synthesis of novel psoralen analogues 2 and 4–6. Reagents and conditions: (i) NaOH, CHCl3, H2O/ethanol, 60 C, 6 h, 30 min; (ii) ethyl acetoacetate, H2SO4, 18 h, rt;
(iii) carbethoxymethylene-triphenylfosforane, N,N-diethylaniline, 130 C, 30 h; (iv) piperidine, AcOH, diethylmalonate, ethanol, 90 C, 5 h; (v) NaOH, ethanol, 60 C, 4 h.
C. S. Francisco et al. / Bioorg. Med. Chem. 21 (2013) 5047–5053 504910.67 ppm, and H-4 and H-3 at 8.27 and 6.85, respectively, as dou-
blets (J = 8.7 Hz).
Compound 4 was prepared from the 2-hydroxy-9H-carbazole-
1-carbaldehyde, 3, in 27%, by a Wittig reaction followed by closure
to give the pyranone ring. The appearance of two new doublets in
the NMR at d (H) 8.53 and 6.48 ppm for H-1 and H-2, respectively,
agree with the structure.
Reaction of the same aldehydewith diethylmalonate (Scheme 2)
gave the pyranocarbazole 5, with 38% yield. The NMR data were
consistent with the proposed structure, namely the singlet at
9.26 ppm for H-1 and the signals for the ester group. Basic hydro-
lysis of the ester 5 gave the corresponding acid derivative 6 in
quantitative yield.
2.2. Antiproliferative effect on human cancer cell lines
The ability of the compounds 1, 2 and 4–6 to inhibit the in vitro
growth of MDA MB231, HeLa and TCC-SUP cell lines was evaluated
and the results, given in concentrations that were able to cause 50%
of cell growth inhibition (GI50), are summarized in Table 1.
A great antiproliferative activity was observed for all the com-
pounds even at the minimum concentration tested (0.5 lM). Com-
pound 1 was found to be the most active against MDA MB231 andTable 1
Antiproliferative effect of the studied compounds on human cancer cell lines
Compound Inhibition of cancer cell lines GI50a (lM)
MDA MB231 HeLa TCC-SUP
1 0.060 ± 0.002 0.035 ± 0.001 0.041 ± 0.007
2 0.078 ± 0.009 0.042 ± 0.005 0.066 ± 0.005
4 0.230 ± 0.019 0.046 ± 0.006 0.027 ± 0.009
5 0.413 ± 0.031 0.037 ± 0.003 0.030 ± 0.004
6 0.265 ± 0.027 0.047 ± 0.008 0.018 ± 0.003
a Data are expressed as average ± S.D. of three independent experiments with
four replicates per concentration in each experiment.HeLa cells, while for TCC-SUP cells, the compound that showed a
higher antiproliferative effect was compound 6, although similar
to compounds 4 and 5. These results are in accordance with a num-
ber of studies that demonstrate the antiproliferative potential of
furocoumarins against several cancer cell lines.17,19,43,44
2.3. Molecular docking
The enzymes from the cytochrome P450 family are involved in
the metabolism of several pharmaceuticals, carcinogens, and a
large number of coumarin-type alkaloids.45,46 Regarding the nature
of this work, CYP2A6 is of particular interest since it has been re-
ported to metabolize indoles, as well as several coumarin ana-
logues.47,48 For instance, bergapten is a potent inhibitor of
CYP2A6 and contributes to cancer cell death and increased sensi-
tivity to chemotherapy in several types of cancer,49,21 in vitiligo
and psoriasis diseases.5,38,50 The antiproliferative effect of bergap-
ten has been demonstrated on several cancer cell lines, including
B16F10 (melanoma cells), gastric adenocarcinoma (MK-1), breast
cancer (MCF-7 and T47D), and hepatocellular carci-
noma.17,19,21,49,51 Likewise, bergapten’s cytotoxic effect was shown
against HeLa51,52 and MDA MB 23119,43,44 cell lines, which are the
ones under study in the present work. To date, no study has been
reported on bergapten effects against TCC-SUP cells. Bergapten
has a similar scaffold to the new tetracyclic coumarin derivatives
that are studied in this work and only differ in the group that is at-
tached to the coumarin ring, that is, it has a pyrrole instead of a fur-
an ring attached to the coumarin. This signiﬁes that the novel
tetracyclic benzofurocoumarin analogues, described here, are good
candidates to act as potential targets of this enzyme.
The co-crystallized X-ray structure of bergapten in CYP2A6
(PDB code 1Z11) reveals that the substrate ﬁts very well in the nar-
row binding site. The active site is formed by a cluster of phenylal-
anine residues (Phe107, Phe111, Phe108, Phe209 and Phe480) that
line the ‘roof’ of the active site and by the presence of a single polar
residue, Asn297 (Fig. 2). It is suggested that Asn297 inﬂuences sub-
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for substrate recognition and binding.53–55 Indeed, mutations of
this residue often lead to dramatic changes in the kinetics of the
reaction that is catalysed by this enzyme.56
The molecular docking results undertaken in this study have
shown that all the studied compounds bind in the same region of
the protein nearby the heme and similarly to what is observed
with the bergapten inhibitor in the X-ray structure 1Z11 (Fig. 2).
The molecular docking results with compounds 1, 2 and 4 have
only provided one binding pose, whereas compounds 5 and 6 have
systematically provided two similar binding poses. This effect
seems to be related with the presence of the bulky ester groups at-
tached to C-3 of the coumarin ring that inﬂuences the binding
mode of these compounds. Interestingly compound 4, which has
the same scaffold of these two compounds but without any group
attached to C-3 of the coumarin ring has only one binding position.
The binding poses of compounds 4, 5 (solution B) and 6 (solution B)
are the closest ones to that observed with the bergapten inhibitor,
in which the C@O group interacts very closely with Asn297
(3.15 Å) and carbon C-9 points towards the iron ion of the heme
co-factor (3.62 Å). The other binding position of compounds 5
and 6 (5A and 6A) have the NH group pointing towards Asn297
(2.45 and 3.65 Å, respectively) and the groups that are attached
to carbon C-3 interacting very closely to the iron ion (2.19 and
2.55 Å, respectively). Regarding the antiproliferative effect on hu-
man cancer cell lines, compounds 5 and 6 are in the majority of
cases worse inhibitors in relation to the other studied compounds,
with the exception of the TCC-SUP cell-lines. Compound 4 system-
atically shows better or comparable results in most cell lines, when
compared with compounds 5 and 6. This suggests that in the latter
cases, the worst inhibitory potency can be related with the lack of
accessibility to the active site, due to the presence of bulky groups
attached to the coumarin moiety and/or the competitive binding
mode that was observed.
The compounds 1 and 2 have the same scaffold and differ only
in the nature of the system that is attached to the coumarin moi-
ety, that is, a benzofuran or an indole, respectively. The docking re-
sults have only shown one binding pose and it closely resembles
what is observed with one of the solutions of compounds 5 and
6 (solutions 5A and 6A), that is, with the C@O group of the couma-
rin moiety interacting very closely with the iron ion of the heme
cluster, instead of with Asn297 (2.3 Å and 2.4 Å, respectively).
However, the results of the antiproliferative effect of the linear 1
and 2 are better than the compounds 4–6. This might be related
with the better accessibility of these compounds to the active site
in relation to the other ones. The only exception refers to the cell-
lines TCC-SUP in which the angular compounds 4–6 gave better re-
sults than the linear ones. It is important to notice that in the case
of TCC-SUP cells, the GI50 values obtained were very low and sim-
ilar among each other for compounds 4–6, thus the differences ob-
served are not statistically signiﬁcant, that is, all the compounds
performed equally well in inhibiting the cancer cells proliferation.
The results also indicate that with the exception of the TCC-SUP
cells, compound 1 has better inhibitory potency than compound 2.
Taking into account the similarity between their structures, these
results suggest that the presence of the pyrrole ring instead of
the furan fused to the coumarin moiety tend to decrease the inhib-
itory efﬁciency of these compounds. This is in line with all the
other pyrrole derivatives that show lower inhibitory properties in
the majority of the studied cell lines.
3. Conclusions
Four new tetracyclic benzopsoralen analogues were synthe-
sized and their biological activity tested. All the compounds werefound to signiﬁcantly inhibit the proliferation of three human tu-
mor cell lines, which we hypothesize to be mainly associated with
the ability that these compounds present to inhibit CYP2A6.
The molecular docking results showed two types of binding
poses in all the studied compounds. Compounds 1 and 2 bind to
the active site with the carbonyl group of the coumarin moiety
pointing towards to the heme cofactor. This is only possible be-
cause of their linear shape that allows them to interact very closely
with the iron of the heme (average distance of 2.2 Å).
In compounds 4–6, the carbonyl group of the coumarin moiety
interacts very closely with Asn297 residue through a hydrogen
bond. Such binding pose is very similar to what is observed with
bergapten (in the bound X-ray structure with the PDB code
1Z11) in which the NH group of the indole ring was found to be
responsible for establishing a similar interaction (compounds 4–
6). However, these compounds do not interact very closely with
the heme cofactor as it is observed with compounds 1 and 2 (aver-
age distance of 3.1 Å).
The molecular docking have also shown that compounds 5 and
6 have another binding pose in the active site that is very similar to
the one that was obtained for compounds 1 and 2 (but not so close
to the heme co-factor—average distance of 2.9 Å). These results
suggest that the presence of bulkier groups at position 2 and 3 of
the coumarin moiety preclude or difﬁcult the binding pose of these
compounds in the active site and to acquire a similar orientation in
relation to what is found with bergapten. The only compound
where this effect is not observed is with compound 4 that does
not contain any substituent on the coumarin moiety. This suggests
that the presence of bulkier groups in the coumarin moiety may be
a preponderant factor for the different binding poses of these com-
pounds as compared to what is observed with bergapten. Interest-
ingly, these compounds are the ones whose binding position is
closer to the heme cofactor and therefore more prone to interact
with it.
The comparison of the binding pose of the compounds 1, 2 and
4–6 in the active site of CYP2A6 and the in vitro antitumor activity
of the studied compounds clearly show that the linear ones, in par-
ticular the compound 1, present the most pronounced activity
against tumor cell lines except for TCC-SUP. The molecular docking
results suggest that the inhibitory efﬁciency of the linear com-
pounds is related to the better accessibility that these compounds
have to the active site in relation to the angular ones.
The results gathered in the current study demonstrate the reac-
tivity of the new psoralen analogues with CYP2A6, an enzyme that
has been related with the bioactivation of carcinogens. Therefore,




Melting points were determined on a Gallenkampmelting point
apparatus and are uncorrected. 1H NMR (300 MHz) and 13C NMR
(75.4 MHz) spectra were recorded on a Varian Unity Plus Spec-
trometer at 298 K or on a Bruker Avance III 400 spectrometer
(400 MHz for 1H and 100.6 MHz for 13C). Chemical shifts are re-
ported in ppm relative to solvent peak or TMS; coupling constants
J are given in Hz. Double resonance, HMQC (heteronuclear multiple
quantum coherence) and HMBC (heteronuclear multiple bond cor-
relation) experiments were carried out for complete assignment of
1H and 13C signals in the NMR spectra. High-resolution mass spec-
tra (EI-TOF or ESI) were obtained on a Waters-Micromass Autospec
M. or on a Bruker FTMS APEXIII spectrometer, respectively. Ele-
mental analyses were performed on a Leco CHNS-932 instrument.
C. S. Francisco et al. / Bioorg. Med. Chem. 21 (2013) 5047–5053 5051TLC was carried out on plates coated with silica gel 60 F254. Column
chromatography was performed on silica gel (70–230 or 230–
400 mesh). Light petroleum refers to the fraction boiling in the
range 40–60 C.
4.1.1. 4-Methyl-2H-benzofuro[2,3-g]chromen-2-one (1)
A mixture of 2-hydroxybenzofuran (0.38 g, 2.0 mmol), ethyl
acetoacetate (0.48 mL, 4.0 mmol) and chilled concd H2SO4 (3 mL)
was stirred at rt for 24 h and further 3 h at 40–50 C. After cooling
the mixture was poured over crushed ice and the beige solid
formed was ﬁltered and dried (0.135 g, 0.54 mmol, 27%). Mp
247–249 C (lit.42 200 C). 1H NMR (400 MHz, DMSO-d6): d 8.25
(dd, J = 8.1, 1.2 Hz, H-10), 8.22 (s, H-11), 8.10 (s, H-5), 7.75 (dd,
J = 9.3, 0.9 Hz, H-7), 7.62 (td, J = 7.5, 1.2 Hz, H-8), 7.45 (td, J = 8.1,
1.2 Hz, H-9), 6.47 (s, H-3), 2.53 (s, CH3) ppm. 13C NMR
(100.6 MHz, DMSO-d6): d 159.91 (C@O), 157.10 (C-6a), 153.36 (C-
4), 151.73 (C-5a), 149.35 (C-11a), 129.42 (C-8), 126.98 (C-10b),
123.50 (C-9), 122.82 (C-10a), 122.38 (C-10), 119.09 (C-4a),
114.29 (C-3), 111.96 (C-7), 108.38 (C-11), 107.139 (C-5), 18.57
(CH3) ppm. HR-(EI-TOF)-MS: calcd for C16H10O3+ m/z 250.0630;
found: 250.0638.
4.1.2. 4-Methylpyrano[2,3-b]carbazol-2(10H)-one (2)
Ethyl acetoacetate (0.16 mL, 1.31 mmol) was added to a solu-
tion of 2-hydroxycarbazole (0.16 g, 0.87 mmol) in ethyl acetate.
The reaction mixture was slowly added to chilled conc H2SO4
(1.6 mL) and stirred at rt for 18 h. After pouring over crushed ice
a brown solid separated and this was ﬁltered and washed with
2 M NaOH solution. Puriﬁcation by CC (SiO2, light petroleum/ethyl
acetate) yielded the product as a beige solid (0.072 g, 0.29 mmol;
33%). Mp 249–251 C. 1H NMR (300 MHz, DMSO-d6): d 11.62 (s,
NH), 8.57 (s, H-5), 8.23 (d, J = 7.8 Hz, H-9), 7.45 (td, J = 8.1, 1.2 Hz,
H-7), 7.51 (d, J = 8.1 Hz, H-6), 7.38 (s, H-11), 7.22 (td, J = 8.1,
1.2 Hz, H-8), 6.24 (s, H-3), 2.57 (s, CH3) ppm. 13C NMR (75.4 MHz,
DMSO-d6): d 160.59 (C@O), 154.36 (C-4), 152.11 (C-11a), 141.98
(Cq), 140.89 (Cq), 126.27 (C-7), 122.20 (Cq), 120.60 (C-9), 120.27
(Cq), 119.55 (C-8), 117.21 (C-5), 112.49 (C-4a), 111.22 (C-6),
110.48 (C-3), 97.16 (C-11), 18.68 (CH3) ppm. HR-(EI-TOF)-MS:
calcd for C16H11NO2+ m/z 249.0790; found: 249.0792.
4.1.3. 2-Hydroxy-9H-carbazole-1-carbaldehyde (3)
A mixture of 2-hydroxycarbazole (0.20 g, 1.09 mmol), H2O/
EtOH (9:1) (6 mL), NaOH (0.40 g, 10.0 mmol) and CHCl3 (0.48 mL)
was heated at 60 C for 5.5 h. After cooling the reaction mixture
was extracted with EtOAc (3  5 mL) and the combined organic
layers were dried (MgSO4), ﬁltered and the solvent evaporated to
dryness. A yellow solid was obtained and puriﬁed by CC (SiO2, light
petroleum/diethyl ether, gradient, 100? 70%) (9.7 mg, 0.05 mmol,
5%). Mp 219–223 C (lit.41c 219–220 C). 1H NMR (300 MHz, ace-
tone-d6): d 11.15 (br s, NH), 10.67 (s, CHO), 10.30 (br s, OH), 8.27
(d, J = 8.7 Hz, H-4), 8.06 (dd, J = 8.4, 1.2 Hz, H-5), 7.70 (dd, J = 7.8,
1.2 Hz, H-8), 7.39 (td, J = 7.8, 1.2 Hz, H-7), 7.24 (td, J = 7.8, 1.2 Hz,
H-6), 6.85 (d, J = 8.7 Hz, H-3) ppm. 13C NMR (100.6 MHz, acetone-
d6): d 191.03 (CHO), 161.68 (C-2), 140.90 (C-8a), 140.60 (C-5a),
129.70 (C-4), 125.63 (C-7), 123.35 (C-4b), 120.94 (C-6), 119.96
(C-5), 117.74 (C-4a), 112.42 (C-8), 108.66 (C-3), 108.20 (C-1)
ppm. Anal. calcd for C13H9NO2.1=4H2O: C, 72.37; H, 4.44; N, 6.49;
found: C, 72.72; H, 4.30; N, 6.57.
4.1.4. Pyrano[3,2-a]carbazol-3(11H)-one (4)
Carbethoxymethylenetriphenylphosphorane (0.22 g, 0.63 mmol)
was added to a solution of 2-hydroxy-9H-carbazole-1-carbalde-
hyde 3 (0.094 g, 0.45 mmol) in N,N-diethylaniline (2 mL) and the
mixture was reﬂuxed for 30 h. After cooling, water (20 mL) was
added and the solution washed with Et2O (4  10 mL). The organic
layer was extracted with 5% HCl (5  10 mL), dried (MgSO4) andconcentrated. A brown oil was obtained which was puriﬁed by pre-
parative layer chromatography (light petroleum/ethyl acetate,
1:1), yielding a light brown solid (0.027 g, 0.12 mmol; 27%). Mp
259–262 C. 1H NMR (400 MHz, acetone-d6): d 11.21 (br, s, NH),
8.53 (d, J = 9.6 Hz, H-1), 8.33 (d, J = 8.8 Hz, H-6), 8.17 (d,
J = 7.6 Hz, H-7), 7.60 (d, J = 8.0 Hz, H-10), 7.45 (t, J = 8.8 Hz, H-9),
7.29 (t, J = 8.0 Hz, H-8), 7.17 (d, J = 9.4 Hz, H-5), 6.48 (d, J = 9.6 Hz,
H-2) ppm. 13C NMR (100.6 MHz, acetone-d6): d 160.89 (C-3),
154.35 (C-4a), 141.05 (C-10a), 139.60 (C-1), 137.06 (C-6b),
126.39 (C-9), 124.68 (C-6), 123,68 (C-10b), 120.88 (C-8), 120.71
(C-7), 120.06 (C-6a), 115.32 (C-2), 112.09 (C-10), 108.81 (C-5),
105.11 (C-4b) ppm. HR-(EI-TOF)-MS: calculated for C15H9NO2+
(M+) m/z 236.0636; found: 235.0633. Anal. calcd for C15H9NO2
1=4H2O: C, 75.14; H, 3.89; N, 5.84; found: C, 75.08; H, 4.14; N, 5.71.
4.1.5. Ethyl 3,11-dihydro-3-oxopyrano[3,2-a]carbazole-2-
carboxylate (5)
Diethylmalonate (60 lL) and 2-hydroxy-9H-carbazole-1-carb-
aldehyde 3 (0.059 g, 0.28 mmol) in EtOH (9 mL) were added to a
solution of piperidine (3 drops) and acetic acid (3 drops) in EtOH
(1 mL). The mixture was reﬂuxed for 5 h and after evaporation a
red oil was obtained. Puriﬁcation by ﬂash chromatography (SiO2,
light petroleum/diethyl ether, gradient, 100? 70%) afforded a yel-
low solid (0.033 g, 0.11 mmol, 38%). Mp 198–201 C (lit.41c 211–
212 C). 1H NMR (400 MHz, acetone-d6): d 11.48 (br s, NH), 9.26
(s, H-1), 8.46 (d, J = 8.4 Hz, H-6), 8.19 (d, J = 8.0 Hz, H-7), 7.65 (d,
J = 8.4 Hz, H-10), 7.48 (dt, J = 7.2, 1.2 Hz, H-9), 7.32 (dt, J = 7.2,
1.2 Hz, H-8), 7.18 (d, J = 8.4 Hz, H-5) ppm. 13C NMR (100.6 MHz,
acetone-d6): d 164.02 (CO ester); 156.87 (C-3), 155.59 (C-4a),
144.72 (C-1), 141.00 (C-10a), 137.91 (C-6b), 127.54 (C-6), 126.65
(C-9), 123.54 (C-10b), 121.25 (C-8), 120.78 (C-7), 120.24 (C-6a),
116.66 (C-2), 112.28 (C-10), 108.30 (C-5), 104.42 (C-4b) ppm. Anal.
calcd for C18H13NO4½H2O: C, 68.35; H, 4.46; N, 4.42; found: C,
68.49; H, 4.69; N, 4.14.
4.1.6. 3,11-Dihydro-3-oxopyrano[3,2-a]carbazole-2-carboxylic
acid (6)
To a solution of the above ester 5 (0.137 g, 0.45 mmol) in hot
EtOH (40 mL), aq NaOH (1 M) (1.34 mL, 1.34 mmol) was added
and the mixture stirred at 60 C for 4 h. After removal of the EtOH,
a solid was obtained which dissolved after addition of water; this
solution was cooled and acidiﬁed with aq HCl (10%). A brown solid
separated which was ﬁltered and dried (0.122 g, 0.43 mmol, 96%).
Mp 312–315 C. 1H NMR (400 MHz, DMSO-d6): d 13.90–13.00
(very br, s, OH), 11.48 (br s, NH), 9.00 (s, H-1), 8.56–8.53 (m, H-
7), 8.33 (d, J = 8.0 Hz, H-6), 8.17-8.13 (m, H-8 or H-9 or H-10),
7.57–7.51 (m, H-8 and/or H-9 and/or H-10), 7.07 (d, J = 8.8 Hz, H-
5) ppm. 13C NMR (100.6 MHz, DMSO-d6): d 164.77 (CO acid);
160.59 (C-3), 157.58 (C-4a), 139.68 (C-1), 137.30 (C-10a), 136.73
(C-6b), 129.13 (C-6), 126.50 (C-8, C-9) or C-10), 126.29 (C-10b),
126.09 (C-8 or C-9 or C-10), 120.67 (C-8 and/or C-9 and/or C-10),
119.33 (C-2), 116.74 (C-7), 114.40 (C-6a), 111.79 (C-5), 106.03
(C-4b) ppm. HR-ESI-MS: calcd for C16H10NO4+ (M+1)+ m/z
280.06043; found: 280.06047. Anal. calcd for C16H9NO4 1=4H2O: C,
67.72; H, 3.37; N, 4.94; found: C, 67.90; H, 3.10; N, 4.84.
4.2. Tumor cell growth assay
The compounds were evaluated for their antiproliferative effect
on human cancer cell lines MDA MB231 (breast adenocarcinoma),
HeLa (cervix adenocarcinoma) and TCC-SUP (bladder transitional
cell carcinoma). The MDA MB231 epithelial cell line was estab-
lished from a pleural effusion obtained from a 51-year-old female
patient with breast cancer. The HeLa cell line was established from
the epithelioid cervix carcinoma of a 31-year-old woman; later
diagnosis changed to adenocarcinoma. The TCC-SUP cell line was
5052 C. S. Francisco et al. / Bioorg. Med. Chem. 21 (2013) 5047–5053established from a tumor specimen resected from the urinary blad-
der transitional cell carcinoma (undifferentiated, grade IV) of a
67-year-old woman. All the cell lines were kindly provided by
IPATIMUP (Portugal). The cells were maintained in an incubator
with a 5% CO2 atmosphere and at 37 C. The culture medium used
was the Dulbecco’s modiﬁed Eagle medium (DMEM) (GIBCO,
Invitrogen, Barcelona, Spain) supplemented with 10% of Fetal Bo-
vine Serum (FBS) (GIBCO, Invitrogen, Barcelona, Spain) (except
for TCC-SUP cell line for which 15% FBS was used) and 1% of pen-
icillin/streptomycin (Invitrogen, Barcelona, Spain).
4.2.1. Cell viability
Cells were exposed to ﬁve concentrations of compounds start-
ing from a maximum concentration of 75 lM. Compounds, pre-
pared in dimethyl sulfoxide (DMSO), were freshly diluted with
cell culture medium just prior the assays. Final concentrations of
DMSO did not interfere with the cell lines growth. The cell viability
was determined using the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] meth-
od. A commercial kit was used according to the manufacturer
instructions (Promega, PROM G35800001, Lisbon, Portugal). In
these experiments, 100 lL of cell suspension was added to each
well of a 96-well plate. Additionally, control wells were included
consisting of DMEM medium and the compounds prepared in
DMSO at the concentrations under study. When a cell concentra-
tion of 1  104 cells/mL was obtained, adequate volumes of the
compounds solutions were added to the wells and incubated for
48 h. Afterwards, 20 lL of the CellTitter 96 AQueous One Solution
Cell Proliferation Assay reagent (MTS) was added to each well
and left in the incubator (37 C, 5% CO2) for 2 h after which the cell
viability was quantiﬁed by recording the absorbance at 490 nm.
For each test compound and for each cell line a dose–response
curve was generated and the growth inhibition of 50% (GI50), cor-
responding to the concentration of compound that inhibits 50% of
the cell growth was determined. The results are expressed as per-
centage of viable cells compared to the control and represent an
average of 3 independent cultures with 4 wells per concentration
in each experiment.
4.3. Molecular docking
All the compounds were studied using the molecular docking
software AutoDock57 and the vsLab plug-in.58 The structure of
the receptor was built from the PDB structure 1Z10 containing
the Human Microsomal P450 2A6. The ligands were built with
GaussView, protonated at physiological pH and optimized with
gaussian09 (Hartree–Fock/6-31G(d)). In the docking process we
used the Lamarckian genetic algorithm (LGA). The number of gen-
erations, energy evaluations, and docking runs were set to 370,000,
1,500,000, and 50, respectively. The types of atomic charges were
taken as Kollman for the receptor. The charges of the ligands are
the Merz–Kollman type of charges that were calculated using the
Gaussian software. The ﬁnal solutions were retrieved from the
molecular docking process according to the criteria of interacting
energy.
Acknowledgements
To the Foundation for the Science and Technology (FCT,
Portugal) for ﬁnancial support to the NMR portuguese network
(PTNMR, Bruker Avance III 400-Univ. Minho). FCT and FEDER
(European Fund for Regional Development)-COMPETE-QREN-EU
for ﬁnancial support to the Research Centre, CQ/UM [PEst-C/QUI/
UI0686/2011 (FCOMP-01-0124-FEDER-022716)], (Pest-C/EQB/
LA0006/2011) and the PhD grant to C.S.F. (SFRH/BD/48636/2008).
The authors also acknowledge the Institute of Molecular Pathologyand Immunology of the University of Porto (IPATIMUP, Porto, Por-
tugal) for kindly providing the breast cancer cell line used in this
work.References and notes
1. Bourgaud, F.; Hehn, A.; Larbat, R.; Doerper, S.; Gontier, E.; Kellner, S.; Matern, U.
Phytochem. Rev. 2006, 5, 293.
2. Chen, C.-Y.; Sun, J.-G.; Liu, F.-Y.; Fung, K.-P.; Wu, P.; Huang, Z.-Z. Tetrahedron
2012, 68, 2598.
3. Gambari, R.; Lampronti, I.; Bianchi, N.; Zuccato, C.; Viola, G.; Vedaldi, D.;
Dall’Acqua, F. Top. Heterocycl. Chem. 2007, 9, 265.
4. Ishikawa, A.; Kuma, T.; Sasaki, H.; Sasaki, N.; Ozeki, Y.; Kobayashi, N.; Kitamura,
Y. Plant Cell Rep. 2009, 28, 257.
5. Adisen, E.; Karaca, F.; Oztas, M.; Gurer, M. A. Clin. Exp. Dermatol. 2008, 33, 344.
6. Grimes, P. E. Clin. Dermatol. 1997, 15, 921.
7. Hovest, M. G.; Krieg, T.; Hermann, G. Exp. Dermatol. 2011, 20, 883.
8. Israel, M.; Schwartz, L. Biomed. Res. 2011, 22, 132.
9. Olguín-Reyes, S.; Camacho-Carranza, R.; Hernández-Ojeda, S.; Elinos-Baez, M.;
Espinosa-Aguirre, J. J. Food Chem. Toxicol. 2012, 50, 3094.
10. Honigsmann, H.; Brenner, W.; Rauschmeier, W.; Konrad, K.; Wolff, K. J. Am.
Acad. Dermatol. 1984, 10, 238.
11. Querfeld, C.; Rosen, S. T.; Kuzel, T. M.; Kirby, K. A.; Roenigk, H. H.; Prinz, B. M.;
Guitart, J. Arch. Dermatol. 2005, 141, 305.
12. Teulings, H. E.; Overkamp, M.; Ceylan, E.; Nieuweboer-Krobotova, L.; Bos, J. D.;
Nijsten, T.; Wolkerstorfer, A. W.; Luiten, R. M.; Van der Veen, J. P. W. Br. J.
Dermatol. 2013, 168, 162.
13. Wang, X.; Lou, Y.-J.; Wang, M.-X.; Shi, Y.-W.; Xu, H.-X.; Kong, L.-D. Toxicol. Lett.
2012, 209, 67.
14. Strauss, U.; Wissel, K.; Jung, S.; Wulff, H.; Hansel, W.; Zhu, J.; Rolfs, A.; Mix, E.
Immunopharmacology 2000, 48, 51.
15. Hafez, O. M.; Amin, K. M.; Abdel-Latif, N. A.; Mohamed, T. K.; Ahmed, E. Y.;
Maher, T. Eur. J. Med. Chem. 2009, 44, 2967.
16. Francisco, C. S.; Rodrigues, L. R.; Cerqueira, N. M. F. S. A.; Oliveira-Campos, A. M.
F.; Rodrigues, L. M. Eur. J. Med. Chem. 2012, 47, 370.
17. Kawaii, S.; Tomono, Y.; Ogawa, K.; Sugiura, M.; Yano, M.; Yoshizawa, Y.
Anticancer Res. 2001, 21, 917.
18. Kawase, M.; Sakagami, H.; Motohashi, N.; Hauer, H.; Chatterjee, S. S.; Spengler,
G.; Vigyikanne, A. V.; Molnar, A.; Molnar, J. In Vivo 2005, 19, 705.
19. Lambertini, E.; Piva, R.; Mahmud, T. H. K.; Lampronti, I.; Bianchi, N.; Borgatti,
M.; Gambari, R. Int. J. Oncol. 2004, 24, 419.
20. Leite, V. C.; Santos, R. F.; Chen, L. C.; Guillo, L. A. J. Photochem. Photobiol., B 2004,
76, 49.
21. Panno, M. L.; Giordano, F.; Rizza, P.; Pellegrino, M.; Zito, D.; Giordano, C.;
Mauro, L.; Catalano, S.; Aquila, S.; Sisci, D.; De Amicis, F.; Vivacqua, A.; Fuqua, S.
W. A.; Ando, S. Breast Cancer Res. Treat. 2012, 136, 443.
22. Scafﬁdi, J. P.; Gregas, M. K.; Lauly, B.; Zhang, Y.; Vo-Dinh, T. ACS Nano 2011, 5,
4679.
23. Yang, X. W.; Xu, B.; Ran, F. X.; Wang, R. G.; Wu, J.; Cui, J. R. J. Chin. Intern. Med.
2007, 5, 56.
24. Wang, Y.; Hong, C.; Zhou, C.; Xu, D.; Qu, H.-b. Evid. Based Complement. Altern.
Med. 2011, 2011, 1.
25. Deans, A. J.; West, S. C. Nat. Rev. Cancer 2011, 11, 467.
26. Kleiner, H. E.; Vulimiri, S. V.; Reed, M. J.; Uberecken, A.; DiGiovanni, J. Chem.
Res. Toxicol. 2002, 15, 226.
27. Fujii-Kuriyama, Y.; Kawajiri, K. Proc. Jpn. Acad. Ser., B, Phys. Biol. Sci. 2010, 86, 40.
28. Guengerich, F. P. Arch. Biochem. Biophys. 2011, 507, 1.
29. Rendic, S. Drug Metab. Rev. 2002, 34, 83.
30. Rodriguez-Fragoso, L.; Martinez-Arismendi, J. L.; Orozco-Bustos, D.; Reyes-
Esparza, J.; Torres, E.; Burchiel, S. W. J. Food Sci. 2011, 76, 112.
31. Marumoto, S.; Oda, Y.; Miyazawa, M. Environ. Mol. Mutagen. 2011, 52, 646.
32. Koenigs, L. L.; Trager, W. F. Biochemistry 1998, 37, 13184.
33. Baumgart, A.; Schmidt, M.; Schmitz, H.-J.; Schrenk, D. Biochem. Pharmacol.
2005, 69, 657.
34. Kleiner, H. E.; Xia, X.; Sonoda, J.; Zhang, J.; Pontius, E.; Abey, J.; Evans, R. M.;
Moore, D. D.; DiGiovanni, J. Toxicol. Appl. Pharmacol. 2008, 232, 337.
35. Koenigs, L.; Peter, R.; Thompson, S.; Rettie, A.; Trager, W. Drug Metab. Dispos.
1997, 25, 1407.
36. Ho, P. C.; Saville, D. J.; Wanwimolruk, S. J. Pharm. Pharm. Sci. 2001, 4, 217.
37. Bariamis, S. E.; Marin, M.; Athanassopoulos, C. M.; Kontogiorgis, C.; Tsimali, Z.;
Papaioannou, D.; Sindona, G.; Romeo, G.; Avgoustakis, K.; Hadjipavlou-Litina,
D. Eur. J. Med. Chem. 2013, 60, 155.
38. Santana, L.; Uriarte, E.; Roleira, F.; Milhazes, N.; Borges, F. Curr. Med. Chem.
2004, 11, 3239.
39. Chilin, A.; Marzano, C.; Guiotto, A.; Manzini, P.; Baccichetti, F.; Carlassare, F.;
Bordin, F. J. Med. Chem. 1999, 42, 2936.
40. Mobilio, S.; Tondelli, L.; Capobianco, M.; Gia, O. Photochem. Photobiol. 1995, 61, 113.
41. (a) Oliveira, A. M. A. G.; Raposo, M. M. M.; Oliveira-Campos, A. M. F.; Grifﬁths,
J.; Machado, A. E. H. Helv. Chim. Acta 2003, 86, 2900; (b) Oliveira, A. M. A. G.;
Raposo, M. M. M.; Oliveira-Campos, A. M. F.; Machado, A. E. H.; Puapairoj, P.;
Pedro, M.; Nascimento, M. S. J.; Portela, C.; Afonso, C.; Pinto, M. Eur. J. Med.
Chem. 2006, 41, 367; (c) Oliveira, A. M. A. G.; Oliveira-Campos, A. M. F.;
Rodrigues, L. M.; Raposo, M. M. M.; Machado, A. E. H.; Nascimento, M. S. J.;
Nazareth, N.; Pinto, M. Chem. Biodivers. 2007, 4, 980.
C. S. Francisco et al. / Bioorg. Med. Chem. 21 (2013) 5047–5053 505342. Farag, N. A. H. Eur. J. Med. Chem. 2009, 44, 18.
43. Chaya, N.; Terauchi, K.; Yamagata, Y.; Kinjo, J.; Okabe, H. Biol. Pharm. Bull. 2004,
27, 1312.
44. Setzer, W. N.; Setzer, M. C.; Schmidt, J. M.; Moriarity, D. M.; Vogler, B.; Reeb, S.;
Holmes, A. M.; Haber, W. A. Planta Med. 2000, 66, 493.
45. Zhou, S.-F.; Liu, J.-P.; Chowbay, B. Drug Metab. Rev. 2009, 41, 89–295.
46. Lamb, D. C.; Waterman, M. R.; Kelly, S. L.; Guengerich, F. P. Curr. Opin.
Biotechnol. 2007, 18, 504.
47. Gillam, E. M. J.; Notley, L. M.; Cai, H. L.; De Voss, J. J.; Guengerich, F. P.
Biochemistry 2000, 39, 13817.
48. Pelkonen, O.; Rautio, A.; Raunio, H.; Pasanen, M. Toxicology 2000, 144, 139.
49. Panno, M. L.; Giordanno, F.; Palma, M. G.; Bartella, V.; Rago, V.; Maggiolini, M.;
Sisci, D.; Lanzino, M.; Amicis, F.; Ando, S. Curr. Cancer Drug Targets 2009, 9, 469.
50. Zonneveld, I. M.; Witkamp, L.; Bossuyt, P. M. M.; Meinardi, M. M. H. M.; Bos, J.
D. J. Eur. Acad. Dermatol. 1997, 9, 232.51. Fujioka, T.; Furumi, K.; Fujii, H.; Okabe, H.; Mihashi, K.; Nakano, Y.; Matsunaga,
M.; Mori, M. Chem. Pharm. Bull. 1999, 47, 96.
52. Gawron, A.; Glowniak, K. Planta Med. 1987, 53, 526.
53. Kim, D.; Wu, Z.; Guengerich, F. J. Biol. Chem. 2005, 280, 40319.
54. Sansen, S.; Yano, J. K.; Reynald, R. L.; Schoch, G. A.; Grifﬁn, K. J.; Stout, C. D.;
Johnson, E. F. J. Biol. Chem. 2007, 282, 14348.
55. Yano, J.; Hsu, M.; Grifﬁn, K.; Stout, C.; Johnson, E. Nat. Struct. Mol. Biol. 2005, 12,
822.
56. Schlicht, K. E.; Berg, J. Z.; Murphy, S. E. Drug Metab. Dispos. 2009, 37, 665.
57. (a) Morris, G.; Goodsell, D.; Huey, R.; Olson, A. J. Comput. Aided Mol. Des. 1996, 10,
293; (b) Morris, G.; Goodsell, D.; Halliday, R.; Huey, R.; Hart, W.; Belew, R.; Olson,
A. J. Comput. Chem. 1998, 19, 139; (c) Morris, G.; Huey, R.; Lindstrom, W.; Sanner,
M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. Comput. Chem. 2009, 30, 2785.
58. Cerqueira, N. M. F. S. A.; Ribeiro, J.; Fernandes, P. A.; Ramos, M. J. Int. J. Quantum
Chem. 2011, 111, 1208.
